PLoS One
2024
Elena Argento, Tashia Petker, Jayesh Vig et al.
3 citations
This study explores therapists' perspectives on experiential learning, competencies, and training in ketamine-assisted therapy (KAT), a form of psychedelic-assisted therapy (PAT). We aim to understand how therapists' personal psychedelic experiences influence their self-perceived competency and therapeutic relationships regarding KAT. Licensed therapists from Numinus Wellness clinics in Canada...
Frontiers in Psychology
2024
Kelley C O'Donnell, Lauren Okano, Michael Alpert et al.
Results from multiple recent studies support further evaluation of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assisted Therapy) in the treatment of post-traumatic stress disorder (PTSD). In two Phase 3 trials, MDMA-Assisted Therapy comprised a short-term, intensive psychotherapy that included three sessions directly facilitated by MDMA (referred to as...
Journal of Addictive Diseases
2024
Alexandra Arenson, Cynthia I Campbell, Ilan Remler
8 citations
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternative treatments. This narrative review aims to educate clinicians on the mechanisms of action, toxicity, and applications of psychoactive plant-based substances patients may be using to self-treat OUD and OW. We specifically discuss ayahuasca, ibogaine,...
Neuropsychopharmacology
2024
Melissa A Simon
6 citations
Psychedelics are a promising approach to caring for persons living with severe mental illness. However, as with all clinical treatments and research in the US, health equity concerns must be considered and addressed. Ensuring health equity and health justice in psychedelic care delivery and research will require strategies to not only reduce disparities and preempt future disparities among...
Pharmacological Research
2024
David B. Yaden, Andrea P Berghella, Peter S. Hendricks et al.
12 citations
Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in treating multiple SUDs, it is possible that these treatments will become legally available options for patients with SUDs in the future. This article highlights how classic psychedelic-assisted therapies might be integrated into current clinical...
Journal of Psychopharmacology
2024
Lisa Bouchet, Zachary Sager, Antoine Yrondi et al.
22 citations
Background: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety,...
Neuropsychiatric Disease and Treatment
2024
Nadav Liam Modlin, Michael Creed, Maria Sarang et al.
18 citations
Post-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy interventions (EBPI) are effective, studies consistently highlight inadequate outcomes and high treatment dropout. Psychedelic therapy (PT) has shown preliminary promise across difficult-to-treat conditions, including MDMA-assisted therapy for PTSD,...
Drug Design, Development and Therapy
2024
Sarah A Norring, Michael G Spigarelli
22 citations
Psilocybin, a tryptamine psychedelic, has been touted in the media both historically and recently as a potential game-changing mental health therapeutic. ClinicalTrials.gov has over one hundred and thirty psilocybin clinical trials listed covering the last twenty years. The single most important aspect of any therapeutic is to gain approval for marketing and thus enter the real-world phase of...
Frontiers in Psychiatry
2024
Marija Franka Žuljević, Nando Breški, Mariano Kaliterna et al.
6 citations
It is important to understand how mental health practitioners view recent findings on psychedelic-assisted psychotherapy (PAP) as there is potential this treatment may be incorporated into clinical practice. The aim of our study was to explore how psychiatrists who are not involved in psychedelic research and who are located in the European region perceive psychedelics and PAP. We conducted...
Revue de l'infirmiere
2024
Caroline Amberger, Laurent Szczesniak
In this article, we aim to highlight the specific role of nurses in the interdisciplinary model of psychedelic-assisted psychotherapy. We argue that the plural competencies of our profession are at the heart of future issues in psychiatry and the use of psychedelics.
Journal of addiction psychiatry
2024
Gianni Martire, Daniel Sipple, David Baron et al.
341 citations
Borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) share overlapping neurobiological mechanisms particularly reward deficiency and stress-like anti-reward processes. And so, BPD may be reclassified as a "traumatic personality stress disorder" (TPSD) with ensuing common therapeutic strategies that may stabilize dopaminergic reward function such as...
Frontiers in Psychiatry
2024
Pablo Sabucedo, Óscar Andión, Robert A Neimeyer et al.
4 citations
Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased attention over the past decades. Evidence-based approaches to prevent PGD are currently scarce, and not always effective. This paper introduces a protocol for a clinical trial exploring the effectiveness of a Meaning Reconstruction psychotherapy...